🚀 VC round data is live in beta, check it out!
Sarepta Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Sarepta Therapeutics and similar public comparables like Nektar Therapeutics, Day One Biopharmaceutical, Mabwell, SK Bioscience and more.
Sarepta Therapeutics Overview
About Sarepta Therapeutics
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Founded
1980
HQ
Employees
1.4K
Website
Sectors
Financials (LTM)
EV
$2B
Sarepta Therapeutics Financials
Sarepta Therapeutics reported last 12-month revenue of $2B and negative EBITDA of ($309M).
In the same LTM period, Sarepta Therapeutics generated $1B in gross profit, ($309M) in EBITDA losses, and had net loss of ($423M).
Revenue (LTM)
Sarepta Therapeutics P&L
In the most recent fiscal year, Sarepta Therapeutics reported revenue of $2B and EBITDA of ($604M).
Sarepta Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Margin | 66% | XXX | 62% | XXX | XXX | XXX |
| EBITDA | ($309M) | XXX | ($604M) | XXX | XXX | XXX |
| EBITDA Margin | (15%) | XXX | (27%) | XXX | XXX | XXX |
| EBIT Margin | (19%) | XXX | (30%) | XXX | XXX | XXX |
| Net Profit | ($423M) | XXX | ($713M) | XXX | XXX | XXX |
| Net Margin | (21%) | XXX | (32%) | XXX | XXX | XXX |
| Net Debt | — | — | $28M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Sarepta Therapeutics Stock Performance
Sarepta Therapeutics has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Sarepta Therapeutics' stock price is $21.18.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | -4.7% | XXX | XXX | XXX | $-6.80 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSarepta Therapeutics Valuation Multiples
Sarepta Therapeutics trades at 1.1x EV/Revenue multiple, and (7.5x) EV/EBITDA.
EV / Revenue (LTM)
Sarepta Therapeutics Financial Valuation Multiples
As of April 11, 2026, Sarepta Therapeutics has market cap of $2B and EV of $2B.
Equity research analysts estimate Sarepta Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sarepta Therapeutics has a P/E ratio of (5.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 1.1x | XXX | 1.1x | XXX | XXX | XXX |
| EV/EBITDA | (7.5x) | XXX | (3.8x) | XXX | XXX | XXX |
| EV/EBIT | (6.1x) | XXX | (3.5x) | XXX | XXX | XXX |
| EV/Gross Profit | 1.7x | XXX | 1.7x | XXX | XXX | XXX |
| P/E | (5.3x) | XXX | (3.1x) | XXX | XXX | XXX |
| EV/FCF | (6.4x) | XXX | (7.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Sarepta Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Sarepta Therapeutics Margins & Growth Rates
Sarepta Therapeutics' revenue in the last 12 month declined by (21%).
Sarepta Therapeutics' revenue per employee in the last FY averaged $1.6M, while opex per employee averaged $1.5M for the same period.
Sarepta Therapeutics' rule of 40 is 4% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sarepta Therapeutics' rule of X is (29%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Sarepta Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (21%) | XXX | (23%) | XXX | XXX | XXX |
| EBITDA Margin | (15%) | XXX | (27%) | XXX | XXX | XXX |
| EBITDA Growth | (221%) | XXX | (176%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 4% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (29%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.6M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.5M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 22% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 60% | XXX | 69% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 92% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Sarepta Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Nektar Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Day One Biopharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Mabwell | XXX | XXX | XXX | XXX | XXX | XXX |
| SK Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca Pharma India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sarepta Therapeutics M&A Activity
Sarepta Therapeutics acquired XXX companies to date.
Last acquisition by Sarepta Therapeutics was on XXXXXXXX, XXXXX. Sarepta Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Sarepta Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSarepta Therapeutics Investment Activity
Sarepta Therapeutics invested in XXX companies to date.
Sarepta Therapeutics made its latest investment on XXXXXXXX, XXXXX. Sarepta Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Sarepta Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Sarepta Therapeutics
| When was Sarepta Therapeutics founded? | Sarepta Therapeutics was founded in 1980. |
| Where is Sarepta Therapeutics headquartered? | Sarepta Therapeutics is headquartered in United States. |
| How many employees does Sarepta Therapeutics have? | As of today, Sarepta Therapeutics has over 1K employees. |
| Who is the CEO of Sarepta Therapeutics? | Sarepta Therapeutics' CEO is Douglas S. Ingram. |
| Is Sarepta Therapeutics publicly listed? | Yes, Sarepta Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Sarepta Therapeutics? | Sarepta Therapeutics trades under SRPT ticker. |
| When did Sarepta Therapeutics go public? | Sarepta Therapeutics went public in 1997. |
| Who are competitors of Sarepta Therapeutics? | Sarepta Therapeutics main competitors are Nektar Therapeutics, Day One Biopharmaceutical, Mabwell, SK Bioscience. |
| What is the current market cap of Sarepta Therapeutics? | Sarepta Therapeutics' current market cap is $2B. |
| What is the current revenue of Sarepta Therapeutics? | Sarepta Therapeutics' last 12 months revenue is $2B. |
| What is the current revenue growth of Sarepta Therapeutics? | Sarepta Therapeutics revenue growth (NTM/LTM) is (21%). |
| What is the current EV/Revenue multiple of Sarepta Therapeutics? | Current revenue multiple of Sarepta Therapeutics is 1.1x. |
| Is Sarepta Therapeutics profitable? | No, Sarepta Therapeutics is not profitable. |
| What is the current EBITDA of Sarepta Therapeutics? | Sarepta Therapeutics has negative EBITDA and is not profitable. |
| What is Sarepta Therapeutics' EBITDA margin? | Sarepta Therapeutics' last 12 months EBITDA margin is (15%). |
| What is the current EV/EBITDA multiple of Sarepta Therapeutics? | Current EBITDA multiple of Sarepta Therapeutics is (7.5x). |
| What is the current FCF of Sarepta Therapeutics? | Sarepta Therapeutics' last 12 months FCF is ($362M). |
| What is Sarepta Therapeutics' FCF margin? | Sarepta Therapeutics' last 12 months FCF margin is (18%). |
| What is the current EV/FCF multiple of Sarepta Therapeutics? | Current FCF multiple of Sarepta Therapeutics is (6.4x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.